Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study

Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study

<b>Purpose:</b> To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) <i>P. aeruginosa</i> infections. <b>Method:</b> This is a multicenter, retrospective cohort study...

Full description

Saved in:
Bibliographic Details
Main Authors: Thamer A. Almangour, Zakiyah Alkherb, Leen Ghonem, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Aminah Alharbi, Nader Damfu, Doaa Aljefri, Jeelan Alghaith, Awaly Alfozan, Ahlam Alghamdi, Ahmad Aljabri, Abdullah A. Alhifany, Mohammed Alessa, Yazed Saleh Alsowaida
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Pharmaceuticals
Subjects:
<i>P. aeruginosa</i>
multidrug-resistant
ceftazidime-avibactam
colistin
Online Access:https://www.mdpi.com/1424-8247/18/1/108
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Purpose:</b> To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) <i>P. aeruginosa</i> infections. <b>Method:</b> This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR <i>P. aeruginosa</i> infections. Outcomes were compared using multivariate logistic regression analysis. <b>Result:</b> Among the screened patients, 203 patients were included: 89 in the CAZ-AVI group and 114 in the colistin group. A total of 57% presented with pneumonia, 21% with bacteremia, and 61% were in the intensive care unit. The rate of clinical cure was significantly higher among patients who received CAZ-AVI (67% vs. 50%; OR, 2.07; 95% CI, 1.16–3.68). The rate of in-hospital mortality was numerically lower among patients who received CAZ-AVI (40% vs. 49%; OR, 0.58; 95% CI, 0.33–1.03). The rate of AKI was significantly lower among patients who received CAZ-AVI (15% vs. 43%; OR, 0.23; 95% CI, 0.11–0.45). <b>Conclusion:</b> CAZ-AVI was more effective in treating MDR <i>P. aeruginosa</i> infections and showed a better safety profile compared to colistin. Thus, CAZ-AVI could be a better alternative for treating MDR <i>P. aeruginosa</i> infections.
ISSN:1424-8247

Similar Items